Prescribing information



The sensor* for the ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder) device provides real data to support your therapeutic decisions

Only available in combination with the ENERZAIR® BREEZHALER® device.




To learn how to use the sensor and Propeller® mobile app with the ENERZAIR® BREEZHALER® device, click here.

Benefits of the sensor* for the ENERZAIR® BREEZHALER® device


Inhalation confirmation for patients1



Enables patients to access real data, with the option to share this with their healthcare professional to support therapeutic decisions.1



Reminders to support enhanced adherence to medication1


The sensor* for the ENERZAIR® BREEZHALER® device is easily accessible 



Available through a simple prescription2

  • The first prescription for ENERZAIR® BREEZHALER® should be written to include a sensor. The sensor battery will last for one year from the day of activation. Repeat prescriptions of ENERZAIR®
    BREEZHALER® during this time will not require a sensor. The mobile app will remind your patient when they should ask you for a new sensor prescription.3


The patient attaches the sensor* to the ENERZAIR® BREEZHALER® device2



The patient accesses a personalised profile and owns their personal data1


*The Propeller® sensor for the BREEZHALER® device (herein referred to as 'the sensor/the sensor for the BREEZHALER® device') and the Propeller® mobile app are property of Propeller Health®.

Indication: ENERZAIR® BREEZHALER® is indicated as a maintenance treatment for asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid, who experienced one or more asthma exacerbations in the previous year.2


  1. Propeller Health®, QR Rationale for EU Classification-2017-B 2019-07-24 Update.
  2. ENERZAIR® BREEZHALER® Summary of Product Characteristics.
  3. The Propellor Sensor for ENERZAIR® BREEZHALER® Quick Start Guide, UG-NSPK_en-US_1.3.000NT 2020-02-17.
Rate this content: 
No votes yet
UK | February 2021 | 103406

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]